ArticleNature communications2019
Engineering a microbial biosynthesis platform for de novo production of tropane alkaloids.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 96 citations in OpenAlex.
- A Comprehensive Review on the Biosynthesis of Tropane Alkaloids.Molecules (Basel, Switzerland) · 2026Review
- Completing the acylation landscape in plants: GDSL enzymes join the BAHD and SCPL acyltransferase families.Journal of experimental botany · 2026Review
- Synthesis of Amines for Active Pharmaceutical Ingredients Using the Whole-Cell Factory Saccharomyces Cerevisae.Chembiochem : a European journal of chemical biology · 2026Review
- Tropanes in natural products, syntheses, and drugs: some insights from the new millennium.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Knocking Out Two Polyphenol Oxidase Genes Significantly Improves Recombinant Protein Purification in Nicotiana benthamiana.Plant biotechnology journal · 2026Article
- Review
- Biotechnological Advances in Sanguinarine and Chelerythrine Production from Plume Poppy (Plants (Basel, Switzerland) · 2025Review
- Unraveling Nature's Pharmacy: Transforming Medicinal Plants into Modern Therapeutic Agents.Pharmaceutics · 2025Review
- Synthetic Biology in Natural Product Biosynthesis.Chemical reviews · 2025Review
- Engineering Saccharomyces cerevisiae for medical applications.Microbial cell factories · 2025Review
- Advances in the biosynthesis of naturally occurring benzylisoquinoline alkaloids.Frontiers in plant science · 2025Review
- Synthetic biology in plants.Plant biotechnology (Tokyo, Japan) · 2024Article
- Plant-Produced Viral Nanoparticles as a Functionalized Catalytic Support for Metabolic Engineering.Plants (Basel, Switzerland) · 2024Article
- Review
- Revealing evolution of tropane alkaloid biosynthesis by analyzing two genomes in the Solanaceae family.Nature communications · 2023Article
- Redirecting tropane alkaloid metabolism reveals pyrrolidine alkaloid diversity in Atropa belladonna.The New phytologist · 2023Article
- Elucidation of tropane alkaloid biosynthesis inProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Comparison of Genome and Plasmid-Based Engineering of Multigene Benzylglucosinolate Pathway in Saccharomyces cerevisiae.Applied and environmental microbiology · 2022Article
- Plant Metabolic Engineering by Multigene Stacking: Synthesis of Diverse Mogrosides.International journal of molecular sciences · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tropane alkaloids (TAs) are a class of phytochemicals produced by plants of the nightshade family used for treating diverse neurological disorders. Here, we demonstrate de novo production of tropine, a key intermediate in the biosynthetic pathway of medicinal TAs such as scopolamine, from simple carbon and nitrogen sources in yeast (Saccharomyces cerevisiae). Our engineered strain incorporates 15 additional genes, including 11 derived from diverse plants and bacteria, and 7 disruptions to yeast regulatory or biosynthetic proteins to produce tropine at titers of 6 mg/L. We also demonstrate the utility of our engineered yeast platform for the discovery of TA derivatives by combining biosynthetic modules from distant plant lineages to achieve de novo production of cinnamoyltropine, a non-canonical TA. Our engineered strain constitutes a starting point for future optimization efforts towards realizing industrial fermentation of medicinal TAs and a platform for the synthesis of TA derivatives with enhanced bioactivities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.